Weon Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weon Kim has a total of 587 co-authors. Here are the top co-authors by number of shared publications:
Jong Shin Woo
Kyung Hee University College of Medicine: Kyung Hee University School of Medicine
29 shared publicationsKyung Hye Lee
Department of Internal Medicine, Division of Cardiovascular, Kyung Hee University Hospital, Kyung Hee University, Seoul, Korea
16 shared publications- Myung Ho Jeong
Department of Cardiology, Chonnam National University Medical School, Gwangju, Korea
14 shared publications Xian Wu Cheng
Department of Internal Medicine, Division of Cardiovascular, Kyung Hee University Hospital, Kyung Hee University, Seoul, Korea
13 shared publications- Jong Shin Woo
Division of Cardiovascular, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, Korea
12 shared publications Haneul Cho
Department of Internal Medicine, Division of Cardiovascular, Kyung Hee University Hospital, Kyung Hee University, Seoul, Korea
10 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Initial Antiplatelet Strategy and 1-Year Outcomes in East Asian Patients With Acute Myocardial Infarction and Renal Dysfunction
Oh S, et al. Korean Circ J. 2027 ;57:e17. https://doi.org/10.4070/kcj.2025.0522
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Open AccessInitial Antiplatelet Strategy and 1-Year Outcomes in East Asian Patients With Acute Myocardial Infarction and Renal Dysfunction
Oh S, et al. Korean Circ J. 2027 ;57:e17. https://doi.org/10.4070/kcj.2025.0522
- 29 October 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
Clopidogrel Versus Aspirin Monotherapy According to Atherothrombotic Risk Profile
BACKGROUND: Clopidogrel monotherapy has shown superior efficacy compared with aspirin after completion of dual antiplatelet therapy following percutaneous coronary intervention (PCI). However, whether treatment effects differ according to overall atherothrombotic risk integrating clinical and angiographic factors remains unclear. METHODS: This post hoc analysis of the SMART-CHOICE 3 (Smart Angioplasty Research Team: Choice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3) randomized trial included patients who completed guideline-directed dual antiplatelet therapy after PCI. Atherothrombotic risk was defined using the a Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention and complex PCI. Patients with Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention ≥3 or complex PCI were classified as higher risk, and those with a Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention P =0.007). In higher-risk patients, clopidogrel reduced major adverse cardiac and cerebrovascular events compared with aspirin (4.6% versus 7.4%; hazard ratio, 0.67 [95% CI, 0.50–0.89]; P =0.006), with no difference in lower-risk patients (3.0% versus 3.2%; hazard ratio, 1.03; P =0.945; interaction P =0.242). Bleeding was similar between groups. CONCLUSIONS: After completion of dual antiplatelet therapy following PCI, clopidogrel monotherapy was associated with lower ischemic risk than aspirin in patients with higher atherothrombotic risk, without increased bleeding. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04418479.
- 29 October 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
Clopidogrel Versus Aspirin Monotherapy According to Atherothrombotic Risk Profile
BACKGROUND: Clopidogrel monotherapy has shown superior efficacy compared with aspirin after completion of dual antiplatelet therapy following percutaneous coronary intervention (PCI). However, whether treatment effects differ according to overall atherothrombotic risk integrating clinical and angiographic factors remains unclear. METHODS: This post hoc analysis of the SMART-CHOICE 3 (Smart Angioplasty Research Team: Choice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3) randomized trial included patients who completed guideline-directed dual antiplatelet therapy after PCI. Atherothrombotic risk was defined using the a Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention and complex PCI. Patients with Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention ≥3 or complex PCI were classified as higher risk, and those with a Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention P =0.007). In higher-risk patients, clopidogrel reduced major adverse cardiac and cerebrovascular events compared with aspirin (4.6% versus 7.4%; hazard ratio, 0.67 [95% CI, 0.50–0.89]; P =0.006), with no difference in lower-risk patients (3.0% versus 3.2%; hazard ratio, 1.03; P =0.945; interaction P =0.242). Bleeding was similar between groups. CONCLUSIONS: After completion of dual antiplatelet therapy following PCI, clopidogrel monotherapy was associated with lower ischemic risk than aspirin in patients with higher atherothrombotic risk, without increased bleeding. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04418479.
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e050187
Restricted Loss of Life Expectancy in Patients With Acute Myocardial Infarction: A Nationwide KAMIR Registry Study
Background: The mortality risk of acute myocardial infarction declines rapidly after the initial period, yet the quantitative measures of residual risk in the follow‐up period remain limited. We aimed to assess restricted loss of life expectancy (LOLE) in patients with acute myocardial infarction. Methods: We included patients from KAMIR (Korea Acute Myocardial Infarction Registry), a nationwide acute myocardial infarction registry, between 2012 and 2020. The survival of 27 705 patients (mean age, 64 years; 76% men) was compared with an age‐, sex‐, and calendar year–matched reference cohort derived from Korean population life tables. Three‐year restricted LOLE was estimated using a Royston–Parmar flexible parametric survival model adjusted for clinical characteristics. Results: Overall, 3‐year restricted LOLE was 23 (95% CI, 22–25) days. In subgroup analyses, older age (≥75 years, 42 [95% CI, 37–47] days versus <50 years, 7 [95% CI, 3–10] days), female sex (44 [95% CI, 37–51] days versus male sex, 14 [95% CI, 11–17] days), and lower left ventricular ejection fraction (≤40%; 135 [95% CI, 128–142] days versus ≥50%, 0 [−2 to 1] days) were associated with higher 3‐year restricted LOLE. Across the study period, 3‐year restricted LOLE nearly halved from 36 (95% CI, 31–41) to 16 (95% CI, 9–23) days. Conclusions: Restricted LOLE provides intuitive, patient‐centered measures of residual risk after acute myocardial infarction. It also demonstrated a significant improvements in patient outcomes over the study period.
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e050187
Restricted Loss of Life Expectancy in Patients With Acute Myocardial Infarction: A Nationwide KAMIR Registry Study
Background: The mortality risk of acute myocardial infarction declines rapidly after the initial period, yet the quantitative measures of residual risk in the follow‐up period remain limited. We aimed to assess restricted loss of life expectancy (LOLE) in patients with acute myocardial infarction. Methods: We included patients from KAMIR (Korea Acute Myocardial Infarction Registry), a nationwide acute myocardial infarction registry, between 2012 and 2020. The survival of 27 705 patients (mean age, 64 years; 76% men) was compared with an age‐, sex‐, and calendar year–matched reference cohort derived from Korean population life tables. Three‐year restricted LOLE was estimated using a Royston–Parmar flexible parametric survival model adjusted for clinical characteristics. Results: Overall, 3‐year restricted LOLE was 23 (95% CI, 22–25) days. In subgroup analyses, older age (≥75 years, 42 [95% CI, 37–47] days versus <50 years, 7 [95% CI, 3–10] days), female sex (44 [95% CI, 37–51] days versus male sex, 14 [95% CI, 11–17] days), and lower left ventricular ejection fraction (≤40%; 135 [95% CI, 128–142] days versus ≥50%, 0 [−2 to 1] days) were associated with higher 3‐year restricted LOLE. Across the study period, 3‐year restricted LOLE nearly halved from 36 (95% CI, 31–41) to 16 (95% CI, 9–23) days. Conclusions: Restricted LOLE provides intuitive, patient‐centered measures of residual risk after acute myocardial infarction. It also demonstrated a significant improvements in patient outcomes over the study period.
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (4) , e25810
Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT
BACKGROUND: Although low-dose triple single-pill combination therapies show promising efficacy and safety, studies comparing them to standard-dose monotherapies remain limited. This phase III, randomized, double-blind trial evaluated the efficacy and safety of a low-dose single-pill combination of telmisartan, amlodipine, and chlorthalidone versus standard-dose telmisartan monotherapy in patients with essential hypertension. METHODS: After a 4-week placebo run-in period, 314 eligible subjects were randomized to either receive telmisartan/amlodipine/chlorthalidone 20/2.5/6.25 mg or telmisartan 40 mg for 8 weeks. The primary efficacy end point was the change in mean sitting systolic blood pressure from baseline to week 8, with noninferiority assessed in the per-protocol set (PPS), followed by superiority testing in the full analysis set using a gatekeeping approach to control for type I error. RESULTS: At week 8, the combination group demonstrated significant mean sitting systolic blood pressure reduction compared with monotherapy in the per-protocol set analysis (least squares mean difference, −3.8 mm Hg [95% CI: −6.7 to −0.9]; P =0.01), establishing its noninferiority. Furthermore, the superiority of the combination therapy was confirmed in the full analysis set (LS mean difference, −4.0 mm Hg [95% CI, −6.8 to −1.3]; P P <0.01). Subgroup analyses showed consistent efficacy across clinical strata, including age and prior antihypertensive treatment. The incidence of adverse events was comparable between groups, with no serious drug-related events reported. CONCLUSIONS: Low-dose triple single-pill combination of telmisartan/amlodipine/chlorthalidone demonstrated superior BP-lowering efficacy with well-tolerated and comparable safety to standard-dose telmisartan monotherapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06348576.
- 1 April 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (4) , e25810
Open AccessLow-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT
BACKGROUND: Although low-dose triple single-pill combination therapies show promising efficacy and safety, studies comparing them to standard-dose monotherapies remain limited. This phase III, randomized, double-blind trial evaluated the efficacy and safety of a low-dose single-pill combination of telmisartan, amlodipine, and chlorthalidone versus standard-dose telmisartan monotherapy in patients with essential hypertension. METHODS: After a 4-week placebo run-in period, 314 eligible subjects were randomized to either receive telmisartan/amlodipine/chlorthalidone 20/2.5/6.25 mg or telmisartan 40 mg for 8 weeks. The primary efficacy end point was the change in mean sitting systolic blood pressure from baseline to week 8, with noninferiority assessed in the per-protocol set (PPS), followed by superiority testing in the full analysis set using a gatekeeping approach to control for type I error. RESULTS: At week 8, the combination group demonstrated significant mean sitting systolic blood pressure reduction compared with monotherapy in the per-protocol set analysis (least squares mean difference, −3.8 mm Hg [95% CI: −6.7 to −0.9]; P =0.01), establishing its noninferiority. Furthermore, the superiority of the combination therapy was confirmed in the full analysis set (LS mean difference, −4.0 mm Hg [95% CI, −6.8 to −1.3]; P P <0.01). Subgroup analyses showed consistent efficacy across clinical strata, including age and prior antihypertensive treatment. The incidence of adverse events was comparable between groups, with no serious drug-related events reported. CONCLUSIONS: Low-dose triple single-pill combination of telmisartan/amlodipine/chlorthalidone demonstrated superior BP-lowering efficacy with well-tolerated and comparable safety to standard-dose telmisartan monotherapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06348576.
- Open Access
- 5 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (3) , 1289
LOw-Dose RAbeprazole Therapy for Reducing Gastrointestinal Events in Patients with High Bleeding Risk (LORA-HBR): A Prospective, Multicenter, Interventional Study
Background: The widespread use of antithrombotic therapies increases bleeding risk, particularly in patients with a high bleeding risk (HBR). Although proton pump inhibitors are recommended for lowering the risk of upper gastrointestinal (UGI) bleeding, the optimal agent and dosage remain uncertain. This study evaluated the efficacy and safety of low-dose rabeprazole (LORA, 5 mg) in reducing the incidence of GI-related adverse events in HBR patients receiving chronic antithrombotic therapy. Methods: This was a prospective, multicenter, interventional study that enrolled 909 South Korean patients receiving long-term antithrombotic therapy with HBR features including age ≥70 years, dual antiplatelet therapy, combined antithrombotic regimens, and prior GI bleeding. The primary endpoint was the incidence of significant GI events, including overt/occult bleeding and symptomatic peptic ulcer disease (PUD). Secondary endpoints included study drug discontinuation owing to GI adverse events, composite cardiovascular events, and all-cause mortality. Results: No patients had significant UGI bleeding or symptomatic PUD. The median adherence rate was 92.0% (interquartile range [IQR], 87.0–95.0). Drug discontinuation owing to GI symptoms occurred in 32 patients (3.52%) at a median of 81 days (IQR, 36–119 days). GI-related adverse events were reported in 3.96%, with diarrhea, epigastric discomfort, and constipation being the most common. Non-GI bleeding and cardiovascular composite events occurred in 0.33% (n = 3) each, with all-cause mortality at 0.55% (n = 5). Conclusions: Low-dose rabeprazole was associated with reduced GI complications in patients receiving chronic antithrombotic therapy, with a favorable safety profile and high adherence. Further studies with larger and broader populations are required to confirm these findings.
- 5 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (3) , 1289
Open AccessLOw-Dose RAbeprazole Therapy for Reducing Gastrointestinal Events in Patients with High Bleeding Risk (LORA-HBR): A Prospective, Multicenter, Interventional Study
Background: The widespread use of antithrombotic therapies increases bleeding risk, particularly in patients with a high bleeding risk (HBR). Although proton pump inhibitors are recommended for lowering the risk of upper gastrointestinal (UGI) bleeding, the optimal agent and dosage remain uncertain. This study evaluated the efficacy and safety of low-dose rabeprazole (LORA, 5 mg) in reducing the incidence of GI-related adverse events in HBR patients receiving chronic antithrombotic therapy. Methods: This was a prospective, multicenter, interventional study that enrolled 909 South Korean patients receiving long-term antithrombotic therapy with HBR features including age ≥70 years, dual antiplatelet therapy, combined antithrombotic regimens, and prior GI bleeding. The primary endpoint was the incidence of significant GI events, including overt/occult bleeding and symptomatic peptic ulcer disease (PUD). Secondary endpoints included study drug discontinuation owing to GI adverse events, composite cardiovascular events, and all-cause mortality. Results: No patients had significant UGI bleeding or symptomatic PUD. The median adherence rate was 92.0% (interquartile range [IQR], 87.0–95.0). Drug discontinuation owing to GI symptoms occurred in 32 patients (3.52%) at a median of 81 days (IQR, 36–119 days). GI-related adverse events were reported in 3.96%, with diarrhea, epigastric discomfort, and constipation being the most common. Non-GI bleeding and cardiovascular composite events occurred in 0.33% (n = 3) each, with all-cause mortality at 0.55% (n = 5). Conclusions: Low-dose rabeprazole was associated with reduced GI complications in patients receiving chronic antithrombotic therapy, with a favorable safety profile and high adherence. Further studies with larger and broader populations are required to confirm these findings.
- Open Access
- 1 January 2026
- Published by XMLink in CardioMetabolic Syndrome Journal
- Vol. 6 (2) , 175-192
Cardiometabolic Syndrome Part 1: Epidemiology, Pathophysiology, and Prevention Strategies
Lim S, et al. Cardiometab Syndr J. 2026 Sep;6(2):175-192. https://doi.org/10.51789/cmsj.2026.6.e25
- 1 January 2026
- Published by XMLink in CardioMetabolic Syndrome Journal
- Vol. 6 (2) , 175-192
Open AccessCardiometabolic Syndrome Part 1: Epidemiology, Pathophysiology, and Prevention Strategies
Lim S, et al. Cardiometab Syndr J. 2026 Sep;6(2):175-192. https://doi.org/10.51789/cmsj.2026.6.e25
- Open Access
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56
2026 Focus Update of the 2021 Korean Society of Myocardial Infarction Expert Consensus Document on Revascularization for Acute Coronary Syndromes
This focused update from the Korean Society of Myocardial Infarction provides consensus recommendations for revascularization in acute coronary syndrome (ACS), integrating major trial evidence since 2021 with Korean real-world practice. A multidisciplinary writing committee reviewed randomized trials, meta-analyses, and recent guidelines, and achieved consensus document. Key recommendations are as follows: 1) Cardiogenic shock: prioritize culprit-first revascularization with early reassessment; apply mechanical circulatory support selectively, guided by shock phenotype and escalation criteria rather than routine use; 2) Non-ST segment elevation ACS: use risk-stratified invasive timing with clear triggers for urgent versus early angiography; 3) Access and imaging: adopt radial-first access and broaden intravascular imaging for complex anatomy, ambiguous culprit lesions, and optimization of stent expansion; 4) Non-culprit lesion: favor complete revascularization in ST-segment elevation myocardial infarction (MI) with multivessel disease; select immediate versus staged procedures based on hemodynamics, ischemic burden, renal function, and contrast load. (5) Special scenarios: implement mechanism-based pathways for MI with non-obstructive coronary arteries and spontaneous coronary artery dissection (SCAD), incorporating intracoronary imaging, functional testing, vasospasm provocation, and cardiac magnetic resonance imaging; prefer conservative treatment for SCAD unless ongoing ischemia persists. The document provides concise "do" statements, and a summary of changes from 2021 to facilitate bedside adoption. These recommendations aim to standardize high-value, patient-centered ACS care in Korea, reduce practice variability, and improve outcomes while acknowledging areas requiring further evidence.
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56
Open Access2026 Focus Update of the 2021 Korean Society of Myocardial Infarction Expert Consensus Document on Revascularization for Acute Coronary Syndromes
This focused update from the Korean Society of Myocardial Infarction provides consensus recommendations for revascularization in acute coronary syndrome (ACS), integrating major trial evidence since 2021 with Korean real-world practice. A multidisciplinary writing committee reviewed randomized trials, meta-analyses, and recent guidelines, and achieved consensus document. Key recommendations are as follows: 1) Cardiogenic shock: prioritize culprit-first revascularization with early reassessment; apply mechanical circulatory support selectively, guided by shock phenotype and escalation criteria rather than routine use; 2) Non-ST segment elevation ACS: use risk-stratified invasive timing with clear triggers for urgent versus early angiography; 3) Access and imaging: adopt radial-first access and broaden intravascular imaging for complex anatomy, ambiguous culprit lesions, and optimization of stent expansion; 4) Non-culprit lesion: favor complete revascularization in ST-segment elevation myocardial infarction (MI) with multivessel disease; select immediate versus staged procedures based on hemodynamics, ischemic burden, renal function, and contrast load. (5) Special scenarios: implement mechanism-based pathways for MI with non-obstructive coronary arteries and spontaneous coronary artery dissection (SCAD), incorporating intracoronary imaging, functional testing, vasospasm provocation, and cardiac magnetic resonance imaging; prefer conservative treatment for SCAD unless ongoing ischemia persists. The document provides concise "do" statements, and a summary of changes from 2021 to facilitate bedside adoption. These recommendations aim to standardize high-value, patient-centered ACS care in Korea, reduce practice variability, and improve outcomes while acknowledging areas requiring further evidence.
- Open Access
- 1 January 2026
- Published by XMLink in Chonnam Medical Journal
- Vol. 62 (2) , 55-63
Clinical Outcomes and Use of Implantable Cardioverter-Defibrillator in Ischemic Heart Failure Patients with Reduced Ejection Fraction: A Retrospective Observational Study
Cho KH, et al. Chonnam Med J. 2026 May;62(2):55-63. https://doi.org/10.4068/cmj.2026.62.2.55
- 1 January 2026
- Published by XMLink in Chonnam Medical Journal
- Vol. 62 (2) , 55-63
Open AccessClinical Outcomes and Use of Implantable Cardioverter-Defibrillator in Ischemic Heart Failure Patients with Reduced Ejection Fraction: A Retrospective Observational Study
Cho KH, et al. Chonnam Med J. 2026 May;62(2):55-63. https://doi.org/10.4068/cmj.2026.62.2.55
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 5 (4) , 339
Antiplatelet Therapy in East Asian Patients With Acute Coronary Syndrome: Current Evidence and Evolving Strategies
Honda S, et al. J Cardiovasc Interv. 2026 ;5:e22. https://doi.org/10.54912/jci.2025.0047
- 1 January 2026
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 5 (4) , 339
Open AccessAntiplatelet Therapy in East Asian Patients With Acute Coronary Syndrome: Current Evidence and Evolving Strategies
Honda S, et al. J Cardiovasc Interv. 2026 ;5:e22. https://doi.org/10.54912/jci.2025.0047
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (8) , e74
Physician Disagreement With Guidelines as a Critical Barrier to Achieving LDL-C Targets in Very High-Risk Patients: An Implementation Science Study
Cho KH, et al. J Korean Med Sci. 2026 Feb;41:e74. https://doi.org/10.3346/jkms.2026.41.e74
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (8) , e74
Open AccessPhysician Disagreement With Guidelines as a Critical Barrier to Achieving LDL-C Targets in Very High-Risk Patients: An Implementation Science Study
Cho KH, et al. J Korean Med Sci. 2026 Feb;41:e74. https://doi.org/10.3346/jkms.2026.41.e74